Bloomberg News

BioCancell Gains on Recruitment for U.S. Ovarian Cancer Trial

May 25, 2009

BioCancell Therapeutics Inc. (BICL) rose for the first time in three days in Tel Aviv trading after the Israeli biotechnology company started recruitment for the clinical trial of its treatment for ovarian cancer.

The stock increased as much as 0.52 shekel, or 17 percent, to 3.57 shekels, and traded up 6.3 percent at 3.24 shekels as of 11:59 a.m. in Israel.

BioCancell said the University of Pennsylvania Medical Center received the regulatory approval to start recruiting patients for the Phase I/IIa of the trial, according to a statement to the Tel Aviv Stock Exchange today.

To contact the reporter on this story: Tal Barak Harif in Tel Aviv at tbarak@bloomberg.net

To contact the editor responsible for this story: Gavin Serkin at gserkin@bloomberg.net


Burger King's Young Buns
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus